nach oben

Erschienen in:

20.03.2017 | Original Article

Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease

verfasst von: Alessandro Pileri, Claudio Agostinelli, Maurizio Sessa, Pietro Quaglino, Marco Santucci, Carlo Tomasini, Vieri Grandi, Paolo Fava, Chiara Astrua, Simona Righi, Annalisa Patrizi, Stefano A. Pileri, Nicola Pimpinelli

Erschienen in: Virchows Archiv | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Mycosis fungoides (MF) is characterized by a switch from indolent behaviour in the early stages to a worse clinical outcome in the advanced ones. Recently, various studies have investigated the role the microenvironment might play in such a switch. We have analysed the distribution of Langerhans cells, plasmacytoid dendritic cells and myeloid-derived suppressor cells in 46 MF cases in various stages, aiming to assess whether changes occur from early to advanced stage. We have investigated the number of langerin, CD303 and arginase-1 positive cells and their distribution at high power. Data were analysed using t test for continuous variables, χ ² tests or Fisher’s exact test for categorical variables, as well as analysis of covariance. In comparing stages IA/B to IIB, we observed a significant decrease in Langerhans cells (p value 0.03) and a significant increase in CD303 and arginase-1 positive cells (p value <0.01 for both markers). Furthermore, a significant increase in Langerhans cells only was observed in stage IIB in comparison to stage III (p = 0.02), while in stage IV, a significant decrease in Langerhans cells was noted in comparison to stage III (p = 0.02). Our data suggest that changes in the microenvironment might influence disease progression, especially from stages IA/B to IIB, opening new scenarios in MF therapy.

Nur mit Berechtigung zugänglich

Pileri A Jr, Patrizi A, Agostinelli C et al (2011) Primary cutaneous lymphomas: a reprisal. Semin Diagn Pathol 28:214–233CrossRefPubMed

Quaglino P, Pimpinelli N, Berti E et al (2012) Mycosis fungoides: disease evolution of the “lion queen” revisited. G Ital Dermatol Venereol 147:523–531PubMed

Scarisbrick JJ, Prince HM, Vermeer MH et al (2015) Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33:3766–3773CrossRefPubMedPubMedCentral

Pimpinelli N, Olsen EA, Santucci M et al (2005) Defining early mycosis fungoides. J Am Acad Dermatol 53:1053–1063CrossRefPubMed

Cerroni L (2006) Lymphoproliferative lesions of the skin. J Clin Pathol 59:813–826CrossRefPubMedPubMedCentral

Wong HK, Mishra A, Hake T et al (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 155:150–166CrossRefPubMedPubMedCentral

Wilcox RA (2016) Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:151–165CrossRefPubMed

Dunn GP, Old LJ, Schreiber RD (2004a) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360CrossRefPubMed

Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998CrossRefPubMed

10.

Dunn GP, Old LJ, Schreiber RD (2004b) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148CrossRefPubMed

11.

Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299CrossRefPubMed

12.

Berger CL, Tigelaar R, Cohen J et al (2005) Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105:1640–1647CrossRefPubMed

13.

Fried I, Cerroni L (2012) FOXP3 in sequential biopsies of progressive mycosis fungoides. Am J Dermatopathol 34:263–265CrossRefPubMed

14.

Goos M, Kaiserling E, Lennert K (1976) Mycosis fungoides: model for T-lymphocyte homing to the skin? Br J Dermatol 94:221–222CrossRefPubMed

15.

Pimpinelli N, Santucci M, Romagnoli P et al (1994) Dendritic cells in T- and B-cell proliferation in the skin. Dermatol Clin 12:255–270PubMed

16.

Lüftl M, Feng A, Licha E et al (2002) Dendritic cells and apoptosis in mycosis fungoides. Br J Dermatol 147:1171–1179CrossRefPubMed

17.

Der-Petrossian M, Valencak J, Jonak C et al (2011) Dermal infiltrates of cutaneous T-cell lymphomas with epidermotropism but not other cutaneous lymphomas are abundant with langerin⁺ dendritic cells. J Eur Acad Dermatol Venereol 25:922–927CrossRefPubMed

18.

Schlapbach C, Ochsenbein A, Kaelin U et al (2010) High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 62:995–1004CrossRefPubMed

19.

Schwingshackl P, Obermoser G, Nguyen VA et al (2012) Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Acta Derm Venereol 92:269–275CrossRefPubMed

20.

Zhang QA, Chen ZQ, Chen MH et al (2014) The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage. Eur Rev Med Pharmacol Sci 18:553–558PubMed

21.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174CrossRefPubMedPubMedCentral

22.

Kumar V, Patel S, Tcyganov E et al (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208–220CrossRefPubMedPubMedCentral

23.

Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969–2975CrossRefPubMedPubMedCentral

24.

Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:641–654CrossRefPubMed

25.

Rodríguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222:180–191CrossRefPubMedPubMedCentral

26.

Strauss L, Sangaletti S, Consonni FM et al (2015) RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis. Cancer Cell 28:253–269CrossRefPubMed

27.

Rodriguez PC, Hernandez CP, Quiceno D et al (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202:931–939CrossRefPubMedPubMedCentral

28.

Serafini P, Mgebroff S, Noonan K et al (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–5449CrossRefPubMedPubMedCentral

29.

Huang B, Pan PY, Li Q et al (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131CrossRefPubMed

30.

Pan PY, Ma G, Weber KJ et al (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70:99–108CrossRefPubMed

31.

Bunt SK, Yang L, Sinha P et al (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026CrossRefPubMedPubMedCentral

32.

Srivastava MK, Sinha P, Clements VK et al (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68–77CrossRefPubMed

33.

Hanson EM, Clements VK, Sinha P et al (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 15(183):937–944CrossRef

34.

Vardhana S, Younes A (2016) The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica 101:794–802CrossRefPubMedPubMedCentral

35.

Wu AA, Drake V, Huang HS et al (2015) Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 4:e1016700CrossRefPubMedPubMedCentral

36.

Dette H, Neumeyer N (2001) Nonparametric analysis of covariance. Ann Stat 29:1361–1400CrossRef

37.

Young SG, Bowman AW (1995) Non-parametric analysis of covariance. Biometrics 51:920–931CrossRef

38.

Wang XF, Ye D (2010) On nonparametric comparison of images and regression surfaces. J Stat Plann Inference 140:2875–2884CrossRef

39.

Gabrilovich D, Ishida T, Oyama T et al (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166PubMed

40.

Pileri A, Agostinelli C, Righi S et al (2015) Vascular endothelial growth factor A (VEGFA) expression in mycosis fungoides. Histopathology 66:173–181CrossRefPubMed

41.

Kim YH, Gratzinger D, Harrison C et al (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119:355–363CrossRefPubMedPubMedCentral

42.

Mauti LA, Le Bitoux MA, Baumer K et al (2011) Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest 121:2794–2807CrossRefPubMedPubMedCentral

43.

Mairhofer DG, Ortner D, Tripp CH et al (2015) Impaired gp100-specific CD8(+) T-cell responses in the presence of myeloid-derived suppressor cells in a spontaneous mouse melanoma model. J Invest Dermatol 135:2785–2793CrossRefPubMedPubMedCentral

44.

Pérez C, González-Rincón J, Onaindia A et al (2015) Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 100:e450–e453CrossRefPubMedPubMedCentral

45.

Dufait I, Van Valckenborgh E, Menu E, et al. (2016) Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget. [Epub ahead of print].

46.

Fava P, Bergallo M, Astrua C, et al. (2016) miR-155 expression in primary cutaneous T- cell lymphomas (CTCL). J Eur Acad Dermatol Venereol. [Epub ahead of print].

47.

Chen S, Zhang Y, Kuzel TM et al (2015) Regulating tumor myeloid-derived suppressor cells by microRNAs. Cancer Cell Microenviron 2:e637PubMedPubMedCentral

48.

Kim S, Song JH, Kim S et al (2016) Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration. Oncotarget 7:11094–11112PubMedPubMedCentral

49.

Sasso MS, Lollo G, Pitorre M et al (2016) Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 96:47–62CrossRefPubMed

50.

He W, Liang P, Guo G et al (2016) Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep 6:24506CrossRefPubMedPubMedCentral

51.

Campbell JJ, Clark RA, Watanabe R et al (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767–771CrossRefPubMedPubMedCentral

Titel: Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease
verfasst von: Alessandro Pileri
Claudio Agostinelli
Maurizio Sessa
Pietro Quaglino
Marco Santucci
Carlo Tomasini
Vieri Grandi
Paolo Fava
Chiara Astrua
Simona Righi
Annalisa Patrizi
Stefano A. Pileri
Nicola Pimpinelli
Publikationsdatum: 20.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2017
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2107-1

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Histopathological findings of extra-ileal manifestations at initial diagnosis of Crohn’s disease-related ileitis

Expression of Rab5a correlates with tumor progression in pancreatic carcinoma

Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels

EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFTE)

Two cases of Mazabraud syndrome and identification of a GNAS R201H mutation by next-generation sequencing

Histopathological findings of extra-ileal manifestations at initial diagnosis of Crohn’s disease-related ileitis

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien